SAR 120.8
(0.0%)
Year | Operating Income | Operating Income Growth |
---|---|---|
2023 | 960.95 Million SAR | -4.15% |
2022 | 1 Billion SAR | 9.03% |
2021 | 919.56 Million SAR | -4.14% |
2020 | 959.27 Million SAR | 18.02% |
2019 | 812.81 Million SAR | 21.77% |
2018 | 667.49 Million SAR | -12.01% |
2017 | 758.57 Million SAR | 0.0% |
Year | Operating Income | Operating Income Growth |
---|---|---|
2024 Q1 | 231.63 Million SAR | -73.22% |
2024 Q3 | 175.8 Million SAR | -35.69% |
2024 Q2 | 273.4 Million SAR | 18.03% |
2023 Q4 | 865.06 Million SAR | 276.47% |
2023 FY | 961 Million SAR | -4.15% |
2023 Q3 | 229.77 Million SAR | -18.78% |
2023 Q2 | 282.92 Million SAR | 7.47% |
2023 Q1 | 263.24 Million SAR | 71.06% |
2022 Q2 | 305.81 Million SAR | 15.67% |
2022 Q1 | 264.37 Million SAR | 65.41% |
2022 Q3 | 278.5 Million SAR | -8.93% |
2022 FY | 1 Billion SAR | 9.03% |
2022 Q4 | 153.89 Million SAR | -44.74% |
2021 FY | 919.56 Million SAR | -4.14% |
2021 Q4 | 159.82 Million SAR | -41.73% |
2021 Q3 | 274.27 Million SAR | 5.64% |
2021 Q2 | 259.63 Million SAR | 14.8% |
2021 Q1 | 226.16 Million SAR | 7.24% |
2020 Q1 | 320 Million SAR | 0.0% |
2020 FY | 959.27 Million SAR | 18.02% |
2020 Q4 | 210.89 Million SAR | 82.96% |
2020 Q3 | 115.26 Million SAR | -62.54% |
2020 Q2 | 307.74 Million SAR | -3.83% |
2019 FY | 812.81 Million SAR | 21.77% |
2018 FY | 667.49 Million SAR | -12.01% |
2017 FY | 758.57 Million SAR | 0.0% |
Name | Operating Income | Operating Income Difference |
---|---|---|
Middle East Pharmaceutical Industries Co. | 78.24 Million SAR | -1128.063% |
Al-Dawaa Medical Services Company | 466.68 Million SAR | -105.909% |
Al-Razi Medical Co. | 1.81 Million SAR | -52920.549% |
Almujtama Alraida Medical Co. | 13.94 Million SAR | -6789.389% |